CISPLATIN INJECTION 1.0 MG — DIN 02403188
CISPLATIN : 1.0 MG · TEVA CANADA LIMITED · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is CISPLATIN INJECTION?
CISPLATIN INJECTION 1.0 MG contains CISPLATIN : 1.0 MG. It is listed in the Health Canada Drug Product Database under DIN 02403188, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 29-Aug-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CISPLATIN INJECTION used for?
Palliative or combination therapy for Metastatic Testicular Tumors, Metastatic Ovarian Tumors (secondary therapy), and Advanced Bladder Cancer (single agent).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Cisplatin cost around the world?
Cisplatin is listed on 8 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); Norway publishes a max AUP (pharmacy retail). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 7 | 13 | SAR███.██ |
| South Africa | single exit price | 10 | 11 | ZAR███.██ |
| Romania | max producer price | 1 | 4 | RON███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Australia | ex-manufacturer | 1 | 2 | AUD███.██ |
| Norway | max AUP (pharmacy retail) | 1 | 2 | NOK███.██ |
| United Arab Emirates | public | 1 | 1 | AED███.██ |
| Greece | producer price (ex-factory) | 1 | 1 | EUR███.██ |
37 pack listings across 25 brand entries and 7 price bases, refreshed 08 Sep 2026. Ranges span every Cisplatin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Cisplatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
12 holders have a Canadian DIN containing Cisplatin, across 13 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ACCORD HEALTHCARE INC | 1 | 1 | CISPLATIN INJECTION, BP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | CISPLATIN INJECTION BP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | CISPLATIN INJECTION BP | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | CISPLATIN INJECTION | Sourceable in Canada |
| DAVID BULL LABORATORIES (PTY) LTD. | 2 | 0 | CISPLATIN INJ 0.5MG/ML, CISPLATIN INJ 1MG/ML | No marketed DIN |
| BRISTOL LABS DIVISION OF BRISTOL-MYERS SQUIBB | 1 | 0 | PLATINOL AQ INJ 1MG/ML | No marketed DIN |
| FRESENIUS KABI CANADA LTD | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | CISPLATIN INJECTION, MYLAN STD. | No marketed DIN |
| OMEGA LABORATORIES LIMITED | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-CISPLATIN | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | CISPLATIN INJECTION BP | No marketed DIN |
| STRIDES PHARMA CANADA INC | 1 | 0 | CISPLATIN INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1.0 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Single-use glass vials of 10 mL (yellow cap), 50 mL (blue cap), and 100 mL (green cap). Individually packaged in cartons. |
| Storage | Not explicitly detailed in provided text (section 11 mentioned in TOC but text cuts off). Diluted solution must be used within 24 hours. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Cisplatin |
|---|---|
| ATC code | L01XA01 |
| AHFS class | 10:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02403188 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2403188 |
| Brand name | CISPLATIN INJECTION |
| Generic / active ingredient | CISPLATIN : 1.0 MG |
| Market authorization holder | TEVA CANADA LIMITED |
| Health Canada schedule | Prescription |
| ATC code | L01XA01 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XA |
| Current status | MARKETED |
| Status date | 29-Aug-2013 |
| Original market date | 2013-08-29 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults/Children: 50-75 mg/m2 IV every 3-4 weeks, or 15-20 mg/m2 IV daily for 5 days every 3-4 weeks. Requires pre-treatment hydration and mannitol. Do not use aluminum components.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Pre-existing renal impairment, hearing impairment, myelosuppression, hypersensitivity to cisplatin or other platinum-containing compounds.
Warnings and precautions
Serious Warnings: Cytotoxic drug. Risk of anaphylaxis, severe myelosuppression, neurotoxicity (leukoencephalopathy), renal toxicity, and cardiovascular toxicity (thromboembolism).
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 13 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02126613 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02536285 |
| CISPLATIN INJECTION, BP | 1 MG | SOLUTION | ACCORD HEALTHCARE INC | MARKETED | 02355183 |
| CISPLATIN INJ 0.5MG/ML | .5 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00644293 |
| CISPLATIN INJ 1MG/ML | 1 MG | LIQUID | DAVID BULL LABORATORIES (PTY) LTD. | CANCELLED POST MARKET | 00692743 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | STRIDES PHARMA CANADA INC | APPROVED | 02393832 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | FRESENIUS KABI CANADA LTD | APPROVED | 02409186 |
| CISPLATIN INJECTION | 1 MG | SOLUTION | OMEGA LABORATORIES LIMITED | APPROVED | 02422034 |
| CISPLATIN INJECTION BP | 1 MG | SOLUTION | SANDOZ CANADA INCORPORATED | CANCELLED POST MARKET | 02366711 |
| CISPLATIN INJECTION, MYLAN STD. | 1 MG | SOLUTION | MYLAN PHARMACEUTICALS ULC | CANCELLED POST MARKET | 02396890 |
2 · Same class — other molecules in ATC L01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Oxaliplatin | ACT OXALIPLATIN · ELOXATIN · OXALIPLATIN · OXALIPLATIN FOR INJECTION · +6 more | 22 | 5 | Yes |
| Cisplatin | CISPLATIN INJ 0.5MG/ML · CISPLATIN INJ 1MG/ML · CISPLATIN INJECTION · CISPLATIN INJECTION BP · +4 more | 13 | 4 | Yes |
| Carboplatin | CARBOPLATIN INJECTION · CARBOPLATIN INJECTION BP · CARBOPLATIN INJECTION LIQ 10MG/ML · CARBOPLATIN INJECTION, BP · +2 more | 10 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XM | Enasidenib · Vorasidenib | 4 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is CISPLATIN INJECTION called?
The same molecule, Cisplatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Cisplatin Accord | Latin | Australia, Norway |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.